Targeson Inc establishes presence in Europe through TouchDown Biomarketing
Contact: Teresa Sunder Prince FOR IMMEDIATE RELEASE
Tel: (858) 427-3675
Email: Teresa.sunderprince@targeson.com
Targeson Inc. Establishes European Presence
San Diego, CA. – January 24, 2011 – In order to support increasing sales of its ultrasound molecular imaging agents, Targeson (www.targeson.com) has established a relationship with TouchDown Biomarketing bv. Touchdown is headquartered in The Netherlands but will provide sales and logistical support throughout Europe for Targeson products. Contact information is:
Targeson Inc. European Sales and support Office, P.O. Box 149, 6680 AC Bemmel, The Netherlands, +31 (0) 13 4626058 Fax: +31 (0) 13 4626059 Email: europe@targeson.com
About TouchDown: TouchDown Biomarketing bv offers sales and marketing, technical and logistical support to life sciences companies to launch and support their products or services into the European market. TouchDown’s offices are based in the Netherlands. www.touchdown-bioinnovation.com
About Targeson Inc: Targeson develops, manufactures and markets ultrasound imaging agents for functional and molecular imaging applications in the research market. Targeson’s commercial products include: Targestar® P, a non-targeted ultrasound contrast agent designed to enhance and quantify blood flow and vascular function; Targestar P-HF, a perfusion contrast agent specifically designed to be used with high frequency ultrasound scanners, such as the Vevo® 770 and Vevo 2100; Targestar SA, a targetable ultrasound contrast agent enabling any biotinylated antibody or biomolecule to be coupled to a microbubble, making it suitable for molecular imaging applications including tumor angiogenesis, myocardial infarction, atherosclerotic plaque, thrombosis, organ transplant rejection and inflammatory diseases; Visistar® Integrin, a targeted ultrasound contrast agent coated with a peptide that binds integrin άvβ3 for molecular imaging of angiogenesis and tumor growth; and Visistar VEGFR2, a targeted ultrasound contrast agent coated with a VEGFR2 binding ligand for molecular imaging of angiogenesis and tumor growth. The VEGFR2 ligand is produced by Sibtech Inc.
back to overview